Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001651308-25-000036
Filing Date
2025-02-28
Accepted
2025-02-28 16:05:55
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A bgne-20241231.htm   iXBRL 10-K/A 76839
2 EX-31.1 exhibit311-2024q410ka.htm EX-31.1 4056
3 EX-31.2 exhibit312-2024q410ka.htm EX-31.2 4048
7 bgne-20241231_g1.jpg GRAPHIC 16225
  Complete submission text file 0001651308-25-000036.txt   329243

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20241231.xsd EX-101.SCH 1782
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20241231_lab.xml EX-101.LAB 35535
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20241231_pre.xml EX-101.PRE 20563
18 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20241231_htm.xml XML 5554
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37686 | Film No.: 25690031
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)